Dana-Farber Cancer Institute

Figure: CD123 targeted drugs approved, recently tested, or currently in trials at Dana-Farber

Andrew Lane, MD, PhD, is exploring next-generation CD123 targeted therapies across acute myeloid leukemia, BPDCN, and other blood cancers. Dive into the physician-focused review here: bit.ly/3JvnCMT

A collage of four photos featuring Dana-Farber staff members wearing a white hat that reads, “Dana-Farber’ on the front.

Show your support for @danafarber.bsky.social and the Jimmy Fund! Your donation today on GivingTuesday will be TRIPLED by Arbella Insurance Group to make 3X the impact AND you will receive a limited-edition Dana-Farber baseball hat.

Donate today: jimmyfund.gives/hk3hfu5u.

Capri smiles while sitting in a hospital crib.

Capri is held by her mom with her dad and two siblings standing around her at a Celtics game.

Today is #GivingTuesday! Your support will help fuel the next lifesaving treatment, research discovery, and victory over cancer for patients like Capri and their families. Make 3X the impact when you donate today: dana-farber.gives/GivingTuesday.

Dana-Farber–Led Studies in Sickle Cell Disease, Waldenström’s, Follicular and Mantle Cell Lymphomas, and MDS Presented at ASH 2025 | Dana-Farber Cancer Institute Dana-Farber Cancer Institute will present more than 120 oral and poster presentations at the 67th American Society for Hematology Annual Meeting and Exposition in Orlando, Florida, December 6 to 9, highlighting advances from lab discoveries to clinical trials that aim to improve patient care and outcomes. Dana-Farber investigators will present data on chemo free, time limited strategies in B cell lymphomas; fixed duration targeted regimens in Waldenström’s macroglobulinemia; mechanistic insights into sickle cell pathobiology; subgroup analyses from a Phase 3 study in higher risk MDS; and patient centered outcomes research in pediatric ALL, and more.

Our researchers are presenting more than 120 studies at #ASH25, covering everything from sickle cell disease and Waldenström’s to Follicular and Mantle Cell Lymphomas and MDS.

View the highlights: bit.ly/4akDLiW

Richard Stone, MD, receiving the Richard L. Schilsky Cancer and Leukemia Group B Achievement Award

Richard Stone, MD, accepting the Richard L. Schilsky Cancer and Leukemia Group B Achievement Award

Richard Stone, MD, award slide

Congratulations to Richard Stone, MD, who has been named the 2025 recipient of the Richard L. Schilsky Cancer and Leukemia Group B Achievement Award by the Alliance for Clinical Trials in Oncology Foundation.

Jacqueline Garcia, MD

Jacqueline Garcia, MD, is exploring ongoing clinical research to test novel triplet therapies for safety and efficacy with a precision medicine approach for patients with acute myeloid leukemia. Explore the latest updates: bit.ly/3LmZEUC

Christopher Lathan, MD, MS, MPH

Please join us in congratulating Christopher Lathan, MD, MS, MPH, as the recipient of this year's Arthur T. Skarin Award on behalf of the Board of Directors of the Massachusetts Society of Clinical Oncologists (MSCO).

Dana-Farber research supports FDA approval of sevabertinib for HER2-mutant lung cancer | Dana-Farber Cancer Institute The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy. The approval reflects a multi-year collaboration led by Dana-Farber Cancer Institute investigators, working closely with colleagues at the Broad Institute.

The @fda.gov approved sevabertinib for HER2-mutant non-small-cell lung cancer, supported by a multi-year research collaboration with colleagues at the @broadinstitute.org. Learn more: bit.ly/49Q2vjd

Anthony Fauci, MD, and Navid Madani, PhD, for Teatime with SHE: Relentless Advocacy, Relentless Science: Honouring the Legacy of Martin Delany in the Global HIV Response

Join Anthony Fauci, MD, and Navid Madani, PhD, on December 2 for the Science Health Education (SHE) Center’s upcoming conversation. Please register and submit questions here: bit.ly/4rdeTzY

President and CEO Benjamin L. Ebert, MD, PhD, at #GlobeSummit2025

At yesterday’s #GlobeSummit2025, our President and CEO Benjamin L. Ebert, MD, PhD, joined Beth Israel Lahey Health and @massbio.bsky.social for an engaging conversation on Funding the Next Cure.

Tandem consult model

Christopher Reilly, MD, and Vincent Ho, MD are optimizing how leukemia and stem cell transplant teams collaborate through a tandem consult model that promotes early alignment of treatment strategy and streamlines coordination of patient care. Learn more: bit.ly/47HNMnw

Three Ways Research Could Improve Pancreatic Cancer Treatment  Published: November 3, 2025Pancreatic cancer has long been difficult to detect and treat. Dana-Farber experts in the  Hale Family Center for Pancreatic Cancer Research, however, are working to change that with research efforts in three key areas that are poised to advance early detection, early intervention, and treatment of the disease.   They presented these topics ... Read more

Pancreatic cancer has long been difficult to detect and treat – but researchers in the Hale Family Center for Pancreatic Cancer Research are working to change that through advances in early detection, RAS-targeted therapies, and immunotherapy. Learn more: bit.ly/4oUm0eH

Eric Smith, MD, PhD

Andrew Aguirre, MD, PhD

Congratulations to Eric Smith, MD, PhD, and Andrew Aguirre, MD, PhD, who are among recipients of the DeGregorio Family Foundation Michael F. Price Memorial Grant. Learn more: bit.ly/4p7qYF0

Dana-Farber and NeighborHealth Partner to Expand Cancer Care Access for Underserved Communities | Dana-Farber Cancer Institute Dana-Farber Cancer Institute and NeighborHealth today announced the launch of a new partnership, bringing world-renowned cancer expertise directly to NeighborHealth patients to help close persistent gaps in cancer diagnosis and treatment.

We’re proud to partner with NeighborHealth to bring world-renowned cancer expertise closer to home for NeighborHealth patients, helping close persistent gaps in cancer diagnosis and treatment. Learn more: bit.ly/4nTTKYz

Dana-Farber Cancer Institute faculty among world's most highly cited researchers | Dana-Farber Cancer Institute Dana-Farber Cancer Institute is proud to announce that 38 of its researchers have been named to the Highly Cited Researchers list of 2025, released today by the Institute for Scientific Information at Clarivate.

@clarivate.com has recognized more than 35 Dana-Farber faculty members on the 2025 Highly Cited Researchers list for the significant and broad contributions they’ve demonstrated in their field of research. Congratulations to all! Learn more: bit.ly/4nTCwKX

Check your eligibility here: bit.ly/3JWs8UI

Dana-Farber launches cancer detection trial for Veterans Dana-Farber Cancer Institute is enrolling veterans in a clinical trial to help detect cancer.

This Veterans Day, @boston25news.com highlights the Sentinel Study – a clinical trial using multi-cancer early detection tests to support veterans, a population at increased risk. Learn more: bit.ly/3LAC9aE

Figure: Menin is a dependency in KMT2Ar and NPM1 mutant leukemia

Menin inhibitors are a promising new class of drugs for acute leukemias. Richard Stone, MD, provides an update on our impact and ongoing clinical research efforts to advance menin inhibitor therapies for acute leukemias, aiming for effective and potentially all-oral treatments: bit.ly/4qL0b2S

William Freed-Pastor, MD, PhD

During Pancreatic Cancer Awareness Month, we’re highlighting new research from Dana-Farber, @mit.edu, and the @broadinstitute.org revealing potential new ways to harness the immune system against pancreatic cancer. Learn more: bit.ly/3Wt0qBN

Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA) receiving the AABB's 2025 President's Award

Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA) receiving the AABB's 2025 President's Award

Congratulations to Olive Sturtevant, MHP, MT(ASCP), SBB, SLS, ASQ (CQA), of our Connell and O'Reilly Families Cell Manipulation Core Facility and recipient of the AABB's 2025 President's Award for her extraordinary dedication and service.

William Gibson, MD, PhD, of Dana-Farber Cancer Institute

New research published in @natchembio.nature.com by @danafarber.bsky.social’s William Gibson, MD, PhD, reveals a general strategy for TP53 missense mutant cancers (majority) with prototype small molecules. @broadinstitute.org

Read more at bit.ly/4onnFJO

Scott Armstrong, MD, PhD

The @fda.gov approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloid leukemia (AML) with NPM1 gene mutations. Learn more: bit.ly/3WEexnN

What happens when targeted therapy meets radiation therapy? Learn about the exciting and innovative form of medicine called radioligand therapy: bit.ly/47vXrxy

New Directions in Treatment for Patients With GIST | CURE Emerging investigational agents may shift the current standard of care for patients with the rare sarcoma known as gastrointestinal stromal tumors.

Dr. Vinayak Venkataraman of @danafarber.bsky.social spoke with @curetoday.bsky.social about how emerging second- and third-line therapeutic strategies and investigational agents may shift the standard of care for patients with GIST.

➡️ bit.ly/3LI7yry

Dana-Farber’s “Sleep ALL Night” Program Helps Children with Leukemia Sleep Better During Treatment | Dana-Farber Cancer Institute Disrupted sleep is a common, often overlooked problem for pediatric patients being treated for acute lymphoblastic leukemia (ALL). To address this issue, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Institute created Sleep ALL Night—a program designed to protect children’s sleep during treatment. 

In a study published in the Journal of Pediatric Psychology, Eric Zhou, PhD, highlights Dana-Farber/Boston Children's Cancer and Blood Disorders Center's new "Sleep ALL Night" program, which aims to help children with leukemia sleep better during treatment. Read more: bit.ly/47NOhO0

Gene activity across tissue. Credit: Filbin lab.

Gene activity across tissue. Credit: Filbin lab.

Back in 2014, there were no targeted therapies approved for childhood brain cancers. Now there are a few, with more on the radar – almost all of which have deep roots in our science. Learn more about how our research is advancing treatment for childhood brain cancer: bit.ly/47hUQZd

What to Know about Lung Cancer in 2025

Please join us for a webinar on What to Know About Lung Cancer.

Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology will share insights on prevention, early detection, and the latest treatment advancements, followed by a Q&A. Register here: bit.ly/3L9ZmjA

Sara Tolaney, MD, of Dana-Farber Cancer Institute

Sara Tolaney, MD, of @danafarber.bsky.social publishes data from DESTINY Breast09 in @nejm.org showing T-DXd plus pertuzumab significantly prolonged progression-free survival compared to standard treatment in first-line therapy for metastatic HER2+ breast cancer.

➡️ bit.ly/3JxnaO5

Dr. Christopher Lathan of Dana-Farber Cancer Institute

Congratulations to Dr. Chris Lathan of @danafarber.bsky.social, recipient of the Randolph W. “Bill” Bromery Legacy Award from @umassamherst.bsky.social for his deep commitment to social justice, diversity, equity, and inclusion.

➡️ bit.ly/4qvbFao

📷 Stephanie Berenson Photography

100 hospitals and health systems with great oncology progra… Becker’s Healthcare is proud to unveil its 2025 list of hospitals and health systems recognized for excellence in oncology. These leading institutions…

We're proud to be included in Becker's 100 hospitals and health systems with great oncology programs 2025 list. Learn more and view the full list here: bit.ly/3Wn6yvj